摘要塞替派是一种烷化剂，目前已被广泛用于多种淋巴造血系统疾病，包括异基因造血干细胞移植预处理、自体造血干细胞移植预处理、原发中枢神经系统淋巴瘤和多种淋巴造血系统疾病的化疗。但是，2019年塞替派在我国重新上市之后，临床医生用药经验较少。基于塞替派目前在我国临床应用的结果，结合国内外相关文献报道，共识专家组成员讨论制定了塞替派在血液淋巴系统肿瘤和造血干细胞移植中临床应用的中国专家共识。

abstractsThiotepa is an alkylating agent that has been widely used in a variety of lymphohematopoietic diseases, including pretreatment for allogeneic hematopoietic stem cell transplantation, pretreatment for autologous hematopoietic stem cell transplantation, primary central nervous system lymphoma and chemotherapy for lymphohematopoietic diseases. However, thiotepa was re-listed in China until 2019, and most physicians has little clinical experience on the use of this agent. Based on the results of the clinical application of thiotepa in China, and the reports in the relevant domestic and foreign literature, the Chinese hematology and oncology experts developed the Chinese expert consensus on the clinical application of thiotepa in hematological and lymphatic system tumors and hematopoietic stem cell transplantation.